- Novavax's COVID-19 vaccine study shows fewer side effects compared to Pfizer-BioNTech's, boosting investor sentiment.
- Analysts predict significant upside potential for NVAX stock, with a high target of $25.00.
- Current valuations suggest possible downside based on GuruFocus's GF Value estimates.
Novavax Inc. (NVAX, Financial) has reported promising preliminary results from the SHIELD-Utah study, highlighting that participants experienced fewer and less severe side effects from its COVID-19 vaccine compared to those from Pfizer-BioNTech. In a week marked by broader market downturns, NVAX shares managed to edge up by 1%, signaling a positive investor response. The stock remains notably undervalued, presenting potential upside for investors.
Wall Street Analysts Forecast
According to insights from six analysts, Novavax Inc. (NVAX, Financial) has an average price target of $17.33, with projections ranging between a high of $25.00 and a low of $9.00. This average target suggests a substantial upside potential of 188.89% from the current trading price of $6.00. For more in-depth estimate data, please visit the Novavax Inc (NVAX) Forecast page.
The consensus recommendation from seven brokerage firms assigns Novavax Inc. (NVAX, Financial) a rating of 2.3, which equates to an "Outperform" status. The rating scale ranges from 1 to 5, with 1 representing a Strong Buy and 5 indicating a Sell.
Based on estimates from GuruFocus, the GF Value for Novavax Inc. (NVAX, Financial) over the next year is calculated to be $5.64, suggesting a potential downside of 6% from the current market price of $6. The GF Value represents GuruFocus's estimate of the fair value at which the stock should ideally be traded, taking into account the historical trading multiples, past business growth, and future business performance projections. Additional details are available on the Novavax Inc (NVAX) Summary page.
